TORONTO, Jan. 23, 2018
/CNW/ - Nuuvera Inc. ("Nuuvera") (TSXV:NUU), is pleased to announce
that ARA-Avanti Rx Analytics Inc. ("Avanti"), a 51% owned
subsidiary of Nuuvera, has entered into a Sale Agreement (the
"Agreement") with Tersum S.A. ("Tersum"), an Uruguayan licensed
producer of cannabis derivatives that is a wholly-owned subsidiary
of ICC Labs Inc. (TSXV:ICC).
According to the Agreement, Avanti will purchase 150 kg of 99%
pure CBD from Tersum in 2018. All CBD will be manufactured in
Tersum's GMP-certified laboratory in Uruguay and subject to rigorous standards
throughout the storage, packaging and shipping process. The
Agreement is subject to the approval of the TSX Venture
Exchange.
"Importing this product through Avanti, a Licensed Dealer in
Canada, reinforces our position as
a global supplier of premium cannabis to Canadians," said
Lorne Abony, CEO of Nuuvera. "All
imported CBD will be tested to ensure that it meets the highest
standards of purity and quality," he continued.
Alejandro Antalich, CEO of ICC Labs Inc., is equally pleased to
have entered into this important relationship. "Nuuvera understands
the importance of identifying global partners to ensure reliable,
quality cannabis products are available to consumers," said Mr.
Antalich. "Canada is leading the
world in making cannabis accessible while ensuring the highest
quality standards, and Nuuvera stands out as an exceptional company
in the global market."
About Nuuvera
Nuuvera is a global cannabis company founded on Canadian
principles, and built with the whole world in mind. Nuuvera is
currently working with partners in Germany, Israel and Italy, and is exploring opportunities in
several other countries, to develop commercial production and
global distribution of medical grade cannabis in legalized markets.
Through its subsidiaries, ARA – Avanti Rx Analytics Inc. and Avalon
Pharmaceutical Inc., Nuuvera holds a Dealer License (GMP) under the
Narcotic Control Regulations and Office of Controlled Substances.
Nuuvera is currently in the final stages of the Health Canada
review process to become a Licensed Producer of medical marijuana
under the ACMPR, and has recently received its "letter to build"
approval.
For more information on Nuuvera, please visit:
www.nuuvera.com
Notice regarding forward-looking statements:
This release includes forward-looking statements regarding
Nuuvera and its business. Often, but not always, forward-looking
statements can be identified by the use of words such as "plans",
"is expected", "expects", "scheduled", "intends", "contemplates",
"anticipates", "believes", "proposes" or variations (including
negative variations) of such words and phrases, or state that
certain actions, events or results "may", "could", "would", "might"
or "will" be taken, occur or be achieved. Such statements are based
on the current expectations of the management of Nuuvera. The
forward-looking events and circumstances discussed in this release
may not occur by certain specified dates or at all and could differ
materially as a result of known and unknown risk factors and
uncertainties affecting Nuuvera, including risks regarding the
cannabis industry, failure to obtain regulatory approvals, economic
factors, the equity markets generally and risks associated with
growth and competition. Although Nuuvera has attempted to identify
important factors that could cause actual actions, events or
results to differ materially from those described in
forward-looking statements, there may be other factors that cause
actions, events or results to differ from those anticipated,
estimated or intended. No forward-looking statement can be
guaranteed. Except as required by applicable securities laws,
forward-looking statements speak only as of the date on which they
are made Nuuvera undertakes no obligation to publicly update or
revise any forward-looking statement, whether as a result of new
information, future events, or otherwise.
Neither the TSX Venture Exchange nor its Regulation Service
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release. The TSX Venture Exchange has in no way
passed upon the merits of the transaction and has neither approved
nor disapproved the content of this press release.
SOURCE Nuuvera Inc.